• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outpatient Treatment for COVID-19.

作者信息

Raglow Zoe, Malani Preeti N, Petty Lindsay A

机构信息

Division of Infectious Diseases, University of Michigan, Ann Arbor.

Deputy Editor, JAMA.

出版信息

JAMA. 2023 Oct 3;330(13):1295. doi: 10.1001/jama.2023.16666.

DOI:10.1001/jama.2023.16666
PMID:37585210
Abstract
摘要

相似文献

1
Outpatient Treatment for COVID-19.新型冠状病毒肺炎的门诊治疗
JAMA. 2023 Oct 3;330(13):1295. doi: 10.1001/jama.2023.16666.
2
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.奥密克戎变异株流行期间，未住院的 2 型糖尿病合并 SARS-CoV-2 感染患者接受莫努匹韦或奈玛特韦/利托那韦治疗后的全因住院和死亡分析。
JAMA Netw Open. 2023 May 1;6(5):e2314393. doi: 10.1001/jamanetworkopen.2023.14393.
3
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19.莫努匹拉韦和奈玛特韦/利托那韦：新型可用的新冠病毒抗病毒药物选择
Acta Med Indones. 2022 Oct;54(4):638-644.
4
Treatment of COVID-19 in high-risk outpatients.高危门诊患者的新冠病毒病治疗
Med Lett Drugs Ther. 2022 Feb 7;64(1643):e1.
5
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.确定并比较莫努匹拉韦和奈玛特韦-利托那韦对新冠病毒肺炎住院患者的实际疗效。
J Korean Med Sci. 2024 Feb 19;39(6):e52. doi: 10.3346/jkms.2024.39.e52.
6
Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.莫努匹韦和奈玛特韦-利托那韦：口服冠状病毒病 2019 抗病毒药物。
Clin Infect Dis. 2023 Jan 6;76(1):165-171. doi: 10.1093/cid/ciac180.
7
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.阿兹夫定、莫努匹韦和奈玛特韦/利托那韦在轻中度 COVID-19 成年患者中的比较：一项回顾性队列研究。
Sci Rep. 2024 Feb 9;14(1):3318. doi: 10.1038/s41598-024-53862-y.
8
Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes.在养老院居住的患者中，使用奈玛特韦/利托那韦和莫努匹韦治疗 COVID-19 的临床结果。
JAMA Netw Open. 2023 Apr 3;6(4):e2310887. doi: 10.1001/jamanetworkopen.2023.10887.
9
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.在欧洲血液系统恶性肿瘤高危COVID-19患者中，莫努匹韦与奈玛特韦/利托那韦的比较。来自EPICOVIDEHA注册研究的配对分析。
Int J Antimicrob Agents. 2023 Oct;62(4):106952. doi: 10.1016/j.ijantimicag.2023.106952. Epub 2023 Aug 13.
10
Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.奈玛特韦/利托那韦或莫努匹韦治疗后 COVID-19 反弹的临床特征：一项前瞻性队列研究。
Medicine (Baltimore). 2023 Sep 29;102(39):e35094. doi: 10.1097/MD.0000000000035094.

引用本文的文献

1
Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022.2022 年台湾成年 COVID-19 患者对奈玛特韦/利托那韦和莫努匹韦的抗病毒药物使用率较低。
J Glob Health. 2024 Nov 8;14:05032. doi: 10.7189/jogh.14.05032.
2
Beliefs about COVID-19 testing and treatment: A national survey of Black and White adults.关于新冠病毒检测与治疗的信念：一项针对黑人和白人成年人的全国性调查。
Public Health Pract (Oxf). 2024 Jun 20;8:100519. doi: 10.1016/j.puhip.2024.100519. eCollection 2024 Dec.
3
Consumption of Meats and Fish in Poland during the COVID-19 Lockdown Period.
波兰在 COVID-19 封锁期间的肉类和鱼类消费情况。
Nutrients. 2024 Apr 27;16(9):1318. doi: 10.3390/nu16091318.